AR-42
CAS No. 935881-37-1
AR-42 ( AR42 | AR 42 | (S)-HDAC-42 | AR-42 | NSC-736012 | OSU-42 )
产品货号. M17674 CAS No. 935881-37-1
AR-42 是一种 HDAC 抑制剂 (IC50: 30 nM)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥445 | 有现货 |
|
| 5MG | ¥748 | 有现货 |
|
| 10MG | ¥1254 | 有现货 |
|
| 25MG | ¥2260 | 有现货 |
|
| 50MG | ¥3432 | 有现货 |
|
| 100MG | ¥4662 | 有现货 |
|
| 200MG | ¥6408 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥822 | 有现货 |
|
生物学信息
-
产品名称AR-42
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述AR-42 是一种 HDAC 抑制剂 (IC50: 30 nM)。
-
产品描述AR-42, also known as (S)-HDAC-42; AR-42; NSC-736012; OSU-42; OSU-HDAC-42; OSUHDAC-42, is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins, which has demonstrated greater potency and activity in solid tumors and hematological malignancies when compared in preclinical studies to vorinostat (also known as "SAHA" or Zolinza?), the first of two marketed compound in the class. AR-42 may possess additional histone-independent mechanisms, which may contribute to its superior profile in vitro and in vivo.
-
体外实验Cell Proliferation Assay Cell Line:Mouse (P815) and canine (C2 and BR) malignant mast cellsConcentration:0.0625, 0.125, 0.25, 0.5, 1 μMIncubation Time:24 hoursResult:Inhibited cell proliferation in a dose-dependent manner, and the median IC50s for P815, C2, and BR cells were 0.65, 0.30, and 0.23 μM, respectively. Cell Cycle Analysis Cell Line:P815,C2 cells Concentration:0.5 μM Incubation Time:24 hours Result:Induced cell-cycle arrest at G1 in the P815 cells and at G1/G2 in the C2 cells.Apoptosis Analysis Cell Line:P815, C2, BR cells Concentration:0.13, 0.25, 0.5, 1 μM Incubation Time:24 hours Result:Caused a dose-dependent induction of apoptosis.Western Blot Analysis Cell Line:P815, C2, BR cell lines Concentration:0.5, 1, 3 μM Incubation Time:24 hours Result:A dose-dependent hyperacetylation of histone H3, histone H4, and α-tubulin.
-
体内实验Animal Model:Nude mice (HepG2 cell tumor xenograft model) Dosage:10 mg/kg Administration:Tail vein injection; twice a week for three weeksResult:Significantly inhibited tumor growth.
-
同义词AR42 | AR 42 | (S)-HDAC-42 | AR-42 | NSC-736012 | OSU-42
-
通路Neuroscience
-
靶点GluR
-
受体HDAC
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number935881-37-1
-
分子量312.36
-
分子式C18H20N2O3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?Ethanol : 50 mg/mL (160.07 mM)
-
SMILESCC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1
-
化学全称(S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Lu Q, et al. J Med Chem, 2005, 48(17), 5530-5535.
产品手册
关联产品
-
LY341495
LY341495 是代谢型谷氨酸受体 (mGluR) 拮抗剂,对 mGlu2,mGlu3,mGlu1a,mGlu5a,mGlu8,mGlu7 和 mGlu4 受体的 IC50 分别为 21 nM,14 nM,7.8 μM,8.2 μM,170 nM,990 nM 和 22 μM。
-
GYKI 52466 dihydroch...
GYKI 52466 dihydrochloride 是一种具有口服活性、高选择性和非竞争性的 AMPA/Kainate 受体拮抗剂,其 IC50 值分别为 7.5 和 11 μM。GYKI 52466 dihydrochloride 具有良好的血脑屏障通透性和抗惊厥作用,可用于帕金森病的研究。
-
Valiglurax
Valiglurax (VU0652957) 是一种口服有效的选择性 mGlu4 正变构调节剂,对 hmGlu4 和 rmGlu4 GIRK 的 EC50 值分别为 64.6 nM 和 197 nM。Valiglurax 是一种中枢神经系统 (CNS) 渗透剂。Valiglurax 可用于帕金森病的研究。
021-51111890
购物车()
sales@molnova.cn

